679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This comprehensive network meta-analysis provides crucial evidence to guide clinical decision-making, offering a head-to-head comparison of incretin drugs that is often unavailable from direct trials. The finding that…
This study provides crucial, evidence-based insights into the comparative efficacy and safety of available GLP-1 RAs, offering a clear hierarchy of their weight reduction capabilities. The findings highlight that newe…
Understanding these sex-specific differences is crucial for advancing personalized medicine approaches in obesity and type 2 diabetes management. This finding suggests that biological sex may be an important factor in…
This study provides compelling evidence that dual and triple incretin agonists offer superior glycemic control and weight loss benefits compared to current GLP-1 receptor agonists for patients with Type 2 Diabetes. Th…
This comprehensive meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in treating both MASLD and MASH, addressing a critical unmet medical need. The significant rates of MASH …
Antiobesity medications offer a dual therapeutic strategy for managing both obesity and the often-coexisting MASLD, a condition with limited approved treatments. This review highlights their potential to become a corn…
This study provides compelling evidence that Retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, offers direct and indirect benefits for kidney health in individuals with Type 2 Diabetes …
This comprehensive NMA provides crucial evidence supporting the superior efficacy of multi-receptor agonists like retatrutide and tirzepatide over single GLP-1 RAs for significant weight loss in adults with overweight…
This study provides compelling evidence that GLP-1 receptor agonists, particularly the more potent multi-agonists, could represent a novel and effective therapeutic class for Alcohol Use Disorder (AUD). By attenuating…
This study provides compelling, high-level evidence that incretin-based therapies offer significant cardiovascular benefits beyond glycemic control and weight management, specifically by consistently lowering blood pr…
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. Th…
This comprehensive review highlights the significant therapeutic potential of GLP-1 agonists as a multi-faceted treatment for PCOS, addressing not only metabolic dysfunction like insulin resistance and obesity but als…
These findings underscore the critical importance of patient-reported outcomes in evaluating novel therapies, revealing that retatrutide offers substantial benefits beyond just weight loss. The observed improvements i…
This comprehensive systematic review provides a critical evidence base for clinicians and patients regarding the expected gastrointestinal side effects of anti-obesity medications. Understanding these common adverse e…
This review provides a critical roadmap for clinicians and researchers, consolidating the evidence for GLP-1 RAs as a cornerstone of modern obesity treatment. Understanding both their profound benefits and inherent li…
The findings from this review underscore a transformative era in the management of diabetic kidney disease, where novel therapies are significantly improving patient prognosis and quality of life. These advancements a…
This review provides a crucial, up-to-date resource for healthcare providers, offering a clear understanding of the current landscape of obesity pharmacotherapy. It underscores the paradigm shift towards highly effect…
Repurposing glucagon represents a significant paradigm shift in the treatment of obesity and type 2 diabetes, offering a novel and powerful approach beyond current single-target therapies. By harnessing its beneficial…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This research highlights a critical public health concern stemming from the proliferation of unregulated compounded GLP-1 RAs sold directly to consumers. The findings underscore the substantial potential for patient s…
Understanding the precise chemical structure and identity of compounds like semaglutide is absolutely critical for pharmaceutical development, ensuring drug purity, consistency, and regulatory compliance. This detaile…
This upcoming clinical trial holds significant promise for patients battling both Type 2 Diabetes and Coronary Arterial Disease, a population at high risk for severe cardiovascular events. If successful, the findings …
The insights gained from this study are crucial for advancing personalized treatment strategies for individuals with co-occurring obesity and Binge Eating Disorder. By understanding how GLP-1 analogues interact with b…
This review critically underscores a significant public health need for more robust research into the safety and efficacy of GLP-1 receptor agonists in reproductive-aged women. Given the global rise in obesity and the…
This review underscores the critical need for integrated care models that combine pharmacological treatment with tailored nutritional guidance. Implementing personalized dietary plans alongside AOMs could significantl…